August 2026       

To Our Shareholders, Employees & Partners:      

The second quarter of 2026 marked a defining milestone in Cumberland's evolution. With the successful completion of our Strategic Transaction, we have entered a new chapter as an innovation-focused biopharmaceutical company committed to developing new medicines for the future. 

We appreciate the support from our shareholders, whose overwhelming approval affirmed our strategy to unlock value while positioning Cumberland for long-term growth. The completion of the transaction strengthens our balance sheet, simplifies our business model and allows us to sharpen our focus on advancing our pipeline and creating value through innovation. 

Furthermore, we were delighted to announce and fund a special dividend to return capital for our shareholders! After the dividend, we have retained sufficient capital to fund operations for the long term, while also maintaining an additional financial reserve for any special opportunities that may arise. Our strong financial position will provide the foundation to execute on our plans for the company’s next phase. 

Our primary focus is now advancing our ifetroban clinical programs, where we continue to make meaningful progress. The momentum generated during the second quarter demonstrates the strength of this strategy and reinforces the opportunities ahead:

During the first quarter, we shared several developments for our product portfolio, including:

  • During the quarter, we shared additional results from our Phase 2 FIGHT DMD trial evaluating ifetroban in patients with Duchenne muscular dystrophy-associated cardiomyopathy at the Parent Project Muscular Dystrophy Annual Conference. The additional biomarker and safety and data further support ifetroban's potential to preserve cardiac function in patients with DMD.
  • We also announced positive Phase 2a results from our clinical collaboration with Vanderbilt Health evaluating ifetroban as a potential therapy to prevent cancer metastasis in patients with high-risk solid tumors. The study met its primary endpoint, demonstrating that ifetroban was safe and well-tolerated. The results also included encouraging efficacy signals, with fewer patients experiencing metastatic recurrence and no metastasis-related deaths in the ifetroban treatment arm. These findings support the continued development of ifetroban as a potential first-in-class therapy targeting the metastatic process, an area of significant unmet medical need.

I would like to take this opportunity thank our Board, employees and investors for their continued confidence and commitment during this transformative period. We are all shareholders and therefore our interests are aligned. We look forward to providing updates on our continued progress as we execute on our strategy, advance our pipeline and build the next generation of growth for our company.

All the best,

AJ's Initials

Please see our corporate website at www.cumberlandpharma.com for links to our product websites for full prescribing and safety information on our brands and for our SEC filings that contain the risk factors associated with our business.